| Clusterin: a key player in cancer chemoresistance and its inhibition T Koltai OncoTargets and therapy, 447-456, 2014 | 183 | 2014 |
| Cancer: fundamentals behind pH targeting and the double-edged approach T Koltai OncoTargets and therapy, 6343-6360, 2016 | 105 | 2016 |
| Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity T Koltai F1000Research 4, 2015 | 76 | 2015 |
| Role of silymarin in cancer treatment: facts, hypotheses, and questions T Koltai, L Fliegel Journal of Evidence-Based Integrative Medicine 27, 2515690X211068826, 2022 | 47 | 2022 |
| Resistance to gemcitabine in pancreatic ductal adenocarcinoma: A physiopathologic and pharmacologic review T Koltai, SJ Reshkin, TMA Carvalho, D Di Molfetta, MR Greco, ... Cancers 14 (10), 2486, 2022 | 42 | 2022 |
| Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs T Koltai F1000Research 4, 2015 | 42 | 2015 |
| Tumor microenvironment features and chemoresistance in pancreatic ductal adenocarcinoma: Insights into targeting physicochemical barriers and metabolism as therapeutic approaches TMA Carvalho, D Di Molfetta, MR Greco, T Koltai, KO Alfarouk, ... Cancers 13 (23), 6135, 2021 | 37 | 2021 |
| An innovative approach to understanding and treating cancer: targeting ph: from etiopathogenesis to new therapeutic avenues T Koltai, SJ Reshkin, S Harguindey Academic Press, 2020 | 20 | 2020 |
| The Ph paradigm in cancer T Koltai European Journal of Clinical Nutrition 74 (Suppl 1), 14-19, 2020 | 18 | 2020 |
| Targeting the ph paradigm at the bedside: A practical approach T Koltai International journal of molecular sciences 21 (23), 9221, 2020 | 14 | 2020 |
| Triple-edged therapy targeting intracellular alkalosis and extracellular acidosis in cancer T Koltai Seminars in Cancer Biology 43, 139-146, 2017 | 14 | 2017 |
| The complex relationship between multiple drug resistance and the tumor pH gradient: a review T Koltai Cancer Drug Resistance 5 (2), 277, 2022 | 11 | 2022 |
| Targeting the stromal pro-tumoral hyaluronan-CD44 pathway in pancreatic cancer T Koltai, SJ Reshkin, TMA Carvalho, RA Cardone International Journal of Molecular Sciences 22 (8), 3953, 2021 | 11 | 2021 |
| Curing cancer? Further along the new pH-centric road and paradigm S Harguindey, T Koltai, SJ Reshkin Oncoscience 5 (5-6), 132, 2018 | 11 | 2018 |
| Fenofibrate in cancer: mechanisms involved in anticancer activity T Koltai F1000Research 4, 55, 2015 | 10 | 2015 |
| Chapter 7—Carbonic Anhydrases T Koltai, SJ Reshkin, S Harguindey An Innovative Approach to Understanding and Treating Cancer: Targeting pH …, 2020 | 5 | 2020 |
| Synergy between low dose metronomic chemotherapy and the pH-centered approach against cancer T Koltai, RA Cardone, SJ Reshkin International Journal of Molecular Sciences 20 (21), 5438, 2019 | 5 | 2019 |
| Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity. F1000Res. 2015; 4: 9 T Koltai Publisher Full Text, 0 | 5 | |
| Prostate cancer metabolism: From biochemistry to therapeutics T Koltai, SJ Reshkin, F Baltazar, L Fliegel Academic Press, 2021 | 3 | 2021 |
| Re-purposing evodiamine as an anti-cancer drug T Koltai Open Access J Oncol Med 1 (3), 37-51, 2018 | 3 | 2018 |
Larry FliegelProfessor of Biochemistry, University of AlbertaVerified email at ualberta.ca
